Page 8 - Solid Tumor News Today

Poseida Therapeutics has hired former Novartis Vice Presiden

The Paws at Play program at St. Jude Children's Research Hospital plays a very important part in helping families cope with their child's diagnosis. They are trained as service dogs that distract patients from their symptoms, illness, pain, and anxiety. They are there to motivate and support too with social interaction.

The shock waves caused by the success of AstraZeneca’s TOPAZ-1 clinical trial have reached Norway. After reviewing the results, PCI Biotech has decided to scrap its own pivotal advanced biliary tract cancer trial in the belief it may struggle to complete the study and win approval. 

Moderna is doling out a little bit of its COVID-19 vaccine cash in a $45 million oncology research deal with Carisma Therapeutics to develop up to a dozen targets.

Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround. 

Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.

A University of Pennsylvania team has developed a new type of engineered immune cell called “peptide-centric” CAR-T that's designed to shrink solid tumors by targeting proteins inside cancer cells. CAR-T cells developed with the technology eradicated neuroblastoma in mouse models and could move into human trials in 2022 or 2023.

/PRNewswire/ -- DelveInsights Bone Metastasis in Solid Tumors Market Insights report proffers a detailed comprehension of Bone Metastasis in Solid Tumors...

Yale University spinout Cybrexa Therapeutics has developed a peptide-drug conjugate that, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. The drug improved the efficacy of checkpoint inhibitors in mouse models of cancer.

Jun 3, 2021 8:40am The setback has led to the winding down of the CART-PSMA-TGFβRDN study. (Image by Dimitris Vetsikas from Pixabay) Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which were first reported by Endpoints, has implications for the broader push to establish cell therapies as treatments for solid tumors. Founded by Carl June, M.D., and Oz Azam, M.D., Tmunity is at the forefron...